Identification and functional characterization of a novel splicing variant in the F8 coagulation gene causing severe hemophilia A.
alternative splicing
hemophilia A
premature stop codon
protein isoforms
synonymous mutation
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
25
06
2019
revised:
30
01
2020
accepted:
10
02
2020
pubmed:
23
2
2020
medline:
15
5
2021
entrez:
21
2
2020
Statut:
ppublish
Résumé
We have identified a synonymous F8 variation in a severe hemophilia A (HA) patient who developed inhibitors following factor VIII (FVIII) prophylaxis. The unreported c.6273 G > A variant targets the consensus splicing site of exon 21. To determine the impact of c.6273 G > A nucleotide substitution on F8 splicing and its translated protein. Patient peripheral blood mononuclear cells were isolated and differentiated into monocyte-derived macrophages (MDMs). FVIII distribution in cell compartments was evaluated by immunofluorescence. The splicing of mutated exon 21 was assessed by exon trapping. Identified FVIII splicing variants were generated by site-directed mutagenesis, inserted into a lentiviral vector (LV) to transduce Chinese hamster ovary (CHO) cells, and inject into B6/129 HA-mice. FVIII activity was assessed by activated partial thromboplastin time, whereas anti-FVIII antibodies and FVIII antigen, by ELISA. HA-MDMs demonstrated a predominant retention of FVIII around the endoplasmic reticulum. Exon trapping revealed the production of two isoforms: one retaining part of intron 21 and the other skipping exon 21. These variants, predicted to truncate FVIII in the C1 domain, were detected in the patient. CHO cells transduced with the two FVIII transcripts confirmed protein retention and absence of the C2 domain. HA mice injected with LV carrying FVIII mutants, partially recovered FVIII activity without the appearance of anti-FVIII antibodies. Herein, we demonstrate the aberrant impact of a FVIII synonymous mutation on its transcription, activity, and pathological outcomes. Our data underline the importance of increasing the knowledge regarding the functional consequences of F8 mutations and their link to inhibitor development and an effective replacement therapy.
Sections du résumé
BACKGROUND
We have identified a synonymous F8 variation in a severe hemophilia A (HA) patient who developed inhibitors following factor VIII (FVIII) prophylaxis. The unreported c.6273 G > A variant targets the consensus splicing site of exon 21.
OBJECTIVES
To determine the impact of c.6273 G > A nucleotide substitution on F8 splicing and its translated protein.
METHODS
Patient peripheral blood mononuclear cells were isolated and differentiated into monocyte-derived macrophages (MDMs). FVIII distribution in cell compartments was evaluated by immunofluorescence. The splicing of mutated exon 21 was assessed by exon trapping. Identified FVIII splicing variants were generated by site-directed mutagenesis, inserted into a lentiviral vector (LV) to transduce Chinese hamster ovary (CHO) cells, and inject into B6/129 HA-mice. FVIII activity was assessed by activated partial thromboplastin time, whereas anti-FVIII antibodies and FVIII antigen, by ELISA.
RESULTS
HA-MDMs demonstrated a predominant retention of FVIII around the endoplasmic reticulum. Exon trapping revealed the production of two isoforms: one retaining part of intron 21 and the other skipping exon 21. These variants, predicted to truncate FVIII in the C1 domain, were detected in the patient. CHO cells transduced with the two FVIII transcripts confirmed protein retention and absence of the C2 domain. HA mice injected with LV carrying FVIII mutants, partially recovered FVIII activity without the appearance of anti-FVIII antibodies.
CONCLUSIONS
Herein, we demonstrate the aberrant impact of a FVIII synonymous mutation on its transcription, activity, and pathological outcomes. Our data underline the importance of increasing the knowledge regarding the functional consequences of F8 mutations and their link to inhibitor development and an effective replacement therapy.
Identifiants
pubmed: 32078252
doi: 10.1111/jth.14779
pii: S1538-7836(22)00322-1
doi:
Substances chimiques
Factor VIII
9001-27-8
Banques de données
GENBANK
['NM_000132.3']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1050-1064Informations de copyright
© 2020 International Society on Thrombosis and Haemostasis.
Références
Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801-1809.
Swystun LL, James P. Using genetic diagnostics in hemophilia and von Willebrand disease. Hematology. 2015;2015:152-159.
White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(03):560-560.
Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038-2044.
Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost. 2010;36(05):493-497.
Jones P. The early history of haemophilia treatment: a personal perspective. Br J Haematol. 2000;111:719-725.
Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117:6367-6370.
Brackmann HH, White GC, Berntorp E, Andersen T, Escuriola-Ettingshausen C. Immune tolerance induction: what have we learned over time? Haemophilia. 2018;24:3-14.
Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet. 1979;2:933.
Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Seminars in Hematology. 2004;41:82-88.
Astermark J. FVIII inhibitors: pathogenesis and avoidance. Blood. 2015;125:2045-2051.
Lakich D, Kazazian HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5:236-241.
Gouw SC, Van Den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119:2922-2934.
Pandey GS, Yanover C, Miller-Jenkins LM, et al. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med. 2013;19:1318-1324.
Sauna Z, Lozier J, Kasper C, Yanover C, Nichols T, Howard T. The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood. 2015;125:223-228.
Lai J, Hough C, Tarrant J, Lillicrap D. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. 2017;129:3147-3154.
Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402-1406.
Boekhorst J, Lari GR, Doiron R, et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia. 2008;14:729-735.
Burset M. Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucleic Acids Res. 2000;28:4364-4375.
Castaman G, Giacomelli SH, Mancuso ME, Sanna S, Santagostino E, Rodeghiero F. F8 mRNA studies in haemophilia A patients with different splice site mutations. Haemophilia. 2010;16:786-790.
Martorell L, Corrales I, Ramirez L, et al. Molecular characterization of ten F8 splicing mutations in RNA isolated from patient’s leucocytes: assessment of in silico prediction tools accuracy. Haemophilia. 2015;21:249-257.
Zimmermann MA, Gehrig A, Oldenburg J, Müller CR, Rost S. Analysis of F8 mRNA in haemophilia A patients with silent mutations or presumptive splice site mutations. Haemophilia. 2013;19:310-317.
Gau JP, Hsu HC, Chau WK, Ho CH. A novel splicing acceptor mutation of the factor VIII gene producing skipping of exon 25. Ann Hematol. 2003;82:175-177.
Tavassoli K, Eigel A, Pollmann H, Horst J. Mutational analysis of ectopic factor VIII transcripts from hemophilia A patients: identification of cryptic splice site, exon skipping and novel point mutations. Hum Genet. 1997;100:5.
Payne AB, Miller CH, Kelly FM, Michael Soucie J, Craig HW. The CDC hemophilia A mutation project (CHAMP) mutation list: a new online resource. Hum Mutat. 2013;34:E2382-E2391.
Giangrande PLF, Peyvandi F, O’Mahony B, et al. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia. 2017;23:370-375.
Zanolini D, Merlin S, Feola M, et al. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A. Haematologica. 2015;100:881-892.
Follo C, Isidoro C. A fast and simple method for simultaneous mixed site-specific mutagenesis of a wide coding sequence. Biotechnol Appl Biochem. 2008;49:175-183.
Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 2002;346:454-465.
Ormiston ML, Toshner MR, Kiskin FN, et al. Generation and culture of blood outgrowth endothelial cells from human peripheral blood. J Vis Exp. 2015;106:e53384.
Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-121.
Merlin S, Famà R, Borroni E, et al. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice. Blood Adv. 2019;3:825-838.
Merlin S, Cannizzo ES, Borroni E, et al. A novel platform for immune tolerance induction in hemophilia A mice. Mol Ther. 2017;25:1815-1830.
Ahmed RPH, Ivaskevicius V, Kannan M, Seifried E, Oldenburg J, Saxena R. Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A. Haematologica. 2005;90.
Castaman G, Giacomelli SH, Ghiotto R, et al. Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene. Haemophilia. 2007;13:311-316.
Green PM, Bagnall RD, Waseem NH, Giannelli F. Haemophilia a mutations in the UK: results of screening one-third of the population. Br J Haematol. 2008;143:115-128.
Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000-31007.
Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem. 1997;272:18007-18014.
Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood. 1990;75:1999-2004.
Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018;59:253-268.
Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. J Am Soc Hematol. 1998;92:3983-3996.
Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997;8(Suppl 2):S3-14.
Canis K, Anzengruber J, Garenaux E, et al. In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications. J Thromb Haemost. 2018;16:1592-1603.
Swaroop M, Moussalli M, Pipe SW, Kaufman RJ. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem. 1997;272:24121-24124.
Pipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998;273:8537-8544.
Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 1994;269:11601-11605.
Scandella D, DeGraaf MS, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci. 1988;85:6152-6156.
Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. 1995;86:1811-1819.
Lövgren KM, Søndergaard H, Skov S, Wiinberg B. Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models. Haemophilia. 2016;22:657-666.
Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133:389-398.
Park CY, Kim DH, Son JS, et al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell Elsevier Inc. 2015;17:213-220.
Park C-Y, Sung JJ, Cho S-R, Kim J, Kim D-W. Universal correction of blood coagulation factor VIII in patient-derived induced pluripotent stem cells using CRISPR/Cas9. Stem Cell Reports ElsevierCompany. 2019;12:1-8.
Olgasi C, Talmon M, Merlin S, et al. Patient-specific iPSC-derived endothelial cells provide long-term phenotypic correction of hemophilia A. Stem Cell Reports ElsevierCompany. 2018;11:1391-1406.